CBPD-268   Click here for help

GtoPdb Ligand ID: 13245

Synonyms: CBPD268 | compound 33 [PMID: 38477974]
Compound class: Synthetic organic
Comment: CBPD-268 is an orally bioactive CBP/p300 PROTAC degrader [1]. The target protein binding component is based on the chemical structure of the CBP/p300 bromodomain inhibitor GNE-049. A new cereblon-binding ligand (TX-16; compound 27 in [2]) is incorporated to engage the E3 ubiquitin ligase.
CBP and p300 are transcriptional coactivators of the androgen receptor (AR) that are found to be abberantly expressed in prostate cancer, and to confer resistance to AR-targeted prostate cancer therapies. CBPD-268 is therefore proposed as an anti-prostate cancer strategy.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 14
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 141.54
Molecular weight 819.9
XLogP 1.87
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(=O)N1CCC2=C(C1)C(=NN2[C@H]3CC[C@@H](CC3)CN4CC5=C(C=C6C(=C5)C(=O)N(C7CCC(=O)NC7=O)C6=O)C4)N8CCCC9=C8C=C(C(=C9)C%10=NN(C)C=C%10)C(F)F
Isomeric SMILES CC(N1CC2=C(N(N=C2N3CCCC4=C3C=C(C(C5=NN(C)C=C5)=C4)C(F)F)[C@H]6CC[C@H](CN7CC8=CC9=C(C=C8C7)C(N(C9=O)C%10CCC(NC%10=O)=O)=O)CC6)CC1)=O
InChI InChI=1S/C44H47F2N9O5/c1-24(56)52-15-12-36-34(23-52)41(53-13-3-4-26-16-30(35-11-14-50(2)48-35)31(40(45)46)19-38(26)53)49-55(36)29-7-5-25(6-8-29)20-51-21-27-17-32-33(18-28(27)22-51)44(60)54(43(32)59)37-9-10-39(57)47-42(37)58/h11,14,16-19,25,29,37,40H,3-10,12-13,15,20-23H2,1-2H3,(H,47,57,58)/t25-,29-,37?
InChI Key ZAGZYDLBQICBCA-UUOOYTBASA-N
References
1. Chen Z, Wang M, Wu D, Bai L, Xu T, Metwally H, Wang Y, McEachern D, Zhao L, Li R et al.. (2024)
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
J Med Chem, [Epub ahead of print]. [PMID:38477974]
2. Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, Miao B, Qin C, Wang M, McEachern D et al.. (2023)
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
J Med Chem, 66 (18): 13280-13303. [PMID:37683104]